## Assessment Schedule

<table>
<thead>
<tr>
<th>Phase</th>
<th>Screening</th>
<th>Baseline</th>
<th>Treatment phase</th>
<th>End of treatment</th>
<th>End of study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit</td>
<td></td>
<td>1</td>
<td>2</td>
<td>3 4 5 6 7 8 9a 9</td>
<td></td>
</tr>
<tr>
<td>Month</td>
<td></td>
<td>1</td>
<td>3</td>
<td>6 9</td>
<td>12</td>
</tr>
</tbody>
</table>

**ENROLLMENT**

- Informed consent X
- Eligibility screen X X
- Transplantation information X
- Randomization X

**INTERVENTIONS**

- Everolimus C0 level X X X X X X X X X
- Tacrolimus C0 level X X X X X X X X X

**ASSESSMENTS**

- Demography X +++
- General medical history X
- Physical examination X X X X X X X X X X X
- Vital signs X X X X X X X X X X X
- Laboratory test: Hemat./Biochemistry X X X X X X X X X
- GFR X X X X X X X X X
- Urinalysis X X X X X X X
- Viral Serology X
- CMV monitoring X X X X X X X
- HCV monitoring X X 4 X 4 X 4 X 4 X 4 X 4 X 4
- Pregnancy test (β-HCG) X X
- Liver Doppler ultrasound X
- Rejection episodes X
- Biopsies X
- Adverse events/infections X As necessary
- Serious adverse events X
- Concomitant therapy X

---

1. Day 21–day of transplantation.
2. Visit 2 (baseline) has to be performed prior to randomization, 7–21 days after Tx.
3. End of treatment visit in case of premature study discontinuation.
4. Only in HCV positive patients.
5. Only in women of childbearing potential.
6. Liver Doppler ultrasound of the hepatic artery, hepatic vein, portal vein, and inferior vena cava will be carried out up to 5 days prior to randomization.